Home / Transcripts / Paysign, Inc. (PAYS) · November 12, 2025

Paysign, Inc. (PAYS) Earnings Call Transcript

November 12, 2025

NASDAQ US Financials Financial Services earnings 35 min

Earnings Call Speaker Segments

Shyamali executive
#1

Good afternoon. I'm Shyamali, and I'll be serving as the conference operator for today's session. Right now, I'd like to extend a welcome to all of you joining the PaySign, Inc. Third Quarter 2025 Earnings Conference Call. Once the speakers have finished their remarks, we'll open things up for a question and answer session. Just a reminder that this call is being recorded. Unless stated otherwise, everything discussed on today's call concerning PaySign's financial results will be presented on a GAAP basis. PaySign's earnings release went out to the SEC earlier today, and you can locate it in the Investor Relations portion of our website, PaySign.com, where reconciliations of non-GAAP measures to GAAP reported amounts are also included. In addition, as laid out in greater detail within the earnings release, I want to remind all of you that forward-looking statements about PaySign's future performance will be part of today's call. Actual performance might differ materially from those forward-looking statements. Details concerning the factors that could impact future performance are summarized at the conclusion of PaySign's earnings release, as well as in its recent SEC filings. Finally, a replay of this call can be accessed until February 12, 2026. For information on how to access the replay, please see PaySign's third quarter 2025 earnings call announcement. I'm now pleased to hand the call over to Mr. Newcomer, President and CEO. Please go ahead. Thank you, and good afternoon, everyone.

Mark R. Newcomer executive
#2

Thanks for being here while we go over what happened in the third quarter of 2025. My name is Mark Newcomer, and I serve as President and CEO of PaySign. With me is Jeff Baker, our CFO. We're also joined by Matt Turner, who is President of Patient Affordability, and Matt Lanford, our Chief Payments Officer; after our prepared comments, both will be around for Q&A. I'm happy to share that PaySign delivered yet another excellent quarter of expansion. This morning, we reported record revenue totaling $21.6 million, which is 41.6% higher than the same period last year. Adjusted EBITDA hit a record $5 million, rising 78%, while net income climbed 54% to $2.2 million, equal to $0.04 per fully diluted share. Beyond those financial figures, we realized significant operational efficiencies, and Jeff will go into greater detail on those in a moment. Our patient affordability segment keeps posting remarkable growth, bringing in $7.9 million of revenue, which is up 142% versus last year's comparable quarter. At the close of the quarter we had 105 active programs, and we expect to bring on 20 to 30 additional ones before the year ends, among them 13 that launched in October. That would put us at 125 to 135 active programs by the close of the year, versus 76 at the end of 2024 — a clear sign of the momentum we've sustained and the growth still ahead. During the quarter we announced that our new patient support center, spanning 30,000 square feet, had opened, marking a major milestone for PaySign. With this expansion, our support capacity grows fourfold, enabling us to handle rising demand and provide an outstanding service experience to our clients, patients, and providers. This facility also underpins an offering of growing value: dedicated patient support representatives, which clients across our base have embraced more and more. What fuels our growth is a full suite of products, top-tier service, clear pricing, and our proprietary dynamic business rules technology. When dynamic business rules are woven into the traditionally commoditized pharmacy claims process, our pharmaceutical clients save hundreds of millions of dollars while creating new revenue streams throughout the patient affordability ecosystem. Our achievements in specialty pharmaceutical programs keep opening doors within the pharmaceutical space, where larger claims volumes and engagements with multi-product manufacturers represent substantial opportunities. Growing our footprint in this area stays a leading priority for our sales teams. Our pipeline is still strong, powered by new as well as existing clients spanning retail and specialty. We expect activity from new drug launches and transition programs already in the queue, and the sales cycle remains steady at about ninety days — a solid indication of dependable execution and demand. Our mission reaches far past payments. We are reshaping how financial assistance gets delivered throughout healthcare, eliminating cost obstacles to treatment and producing measurable savings for patients and our pharmaceutical partners equally. The ongoing strength of the patient affordability business highlights how powerful and scalable our model is. Now to our plasma donor compensation business: revenue increased 12.4% year over year to a record $12.9 million, even with a net loss of 12 centers, which left us with 595 active centers when the quarter ended. Like we've said before, there's still too much sourced plasma on the market across the industry, and we figure that will even out in 2026. On a brighter note, the typical amount paid to donors for each donation went up in the quarter, and that momentum has continued into Q4. Along with encouraging conversations with clients, we believe center-level organic growth could arrive earlier than we'd thought. We're carrying out our plan to broaden what we do within the blood and plasma ecosystem, moving beyond our roots as a dependable payments provider toward becoming a technology partner. Strong interest keeps coming, both at home and abroad, for our Software as a Service engagement platform — that's the donor app, the plasma-specific CRM, and the donor management system, which is also called a blood establishment computer system, or BECCS. While we wait on FDA 510 clearance for the BECCS, we're out there actively presenting the platform to the blood and plasma industry, and they're keen to locate efficient, easy-to-use, affordable options versus what's available today. The response has been extremely favorable, which strengthens our belief in the opportunity this business line holds over the long run. To wrap up, Q3 was an outstanding quarter marked by solid execution and innovation; we're growing efficiently, moving into new markets, and creating transformative value in patient affordability and plasma — two areas where we're changing what people expect and shaking up the status quo. I couldn't be prouder of how our team keeps its focus and discipline. Their commitment to achieving results with purpose keeps fueling our momentum. Going forward, we stay confident about our growth path and remain solidly dedicated to creating long-term value for our shareholders. With that, I'll hand things to Jeff for a deeper dive into the financials.

Jeffery B. Baker executive
#3

Thank you, Mark. Good afternoon to all of you. Like Mark mentioned, we delivered yet another robust quarter, and we keep building momentum as we head toward 2026. Our patient affordability segment captured some excellent wins, spanning both fresh partnerships that brought us several programs and current clients that added more programs with us. During the quarter, our plasma operation achieved year-over-year growth thanks to the new centers we brought on in the second quarter. When the quarter closed, we had 595 active plasma centers along with 105 active patient affordability programs. Even more significant, by the end of October we reached 118 active patient affordability programs, and more are being added every week. Compared to twelve months ago, our total gross profit margins continue to improve, despite the fact that freshly opened plasma centers weigh on those margins since they have not yet reached maturity. Over the next six to nine months, as those new centers mature, we expect to see benefits beyond where we stand today. Additionally, we expect improvements in our overall gross profit margins as the new customer service contact center that launched in September reaches full capacity. Since the company continues to grow and we're still putting money into the workforce and the systems needed to support that growth, we expect both our operating margins and our adjusted EBITDA margins to continue rising compared with the same period a year earlier. That reflects the operating leverage our business has. All told, we have never been more excited about what's coming for the company over the remainder of this year and into 2026. I'd encourage everyone to look at our 10-Q for more information about our financial results; it should be filed tomorrow morning before the market opens. With that, let me turn your attention to the third quarter results. Our results for revenue and adjusted EBITDA exceeded the outlook we provided three months ago. For the third quarter of 2025, total revenues hit $21.6 million, which is an increase of $6.3 million, or 41.6%. Adjusted EBITDA was $5 million, representing a gain of $2.2 million, or 78.1%. Plasma revenue climbed 12.4% to $12.9 million, although revenue per plasma center for us declined to $7,122, as the additional plasma centers brought on in the second quarter are not yet fully mature, and our existing centers continue to feel the impact of the industry-wide plasma oversupply. Gross dollars loaded to cards grew 21%, total loads increased 19.3%, and gross spend volume was up 19.2%, mainly driven by the new centers introduced in the second quarter. On this call, patient affordability revenue rose 142%, reaching $7.9 million, which represented 36.7% of our quarterly revenues. A year earlier, Pharma made up 21.5% of revenue, so this is a significant increase. We added eight net programs, ending the quarter with 105 pharma patient affordability programs, and the number of claims processed grew by over 60% versus the same period last year. Gross profit margin came in at 56.3% for the quarter, up 72 basis points. SG&A, excluding depreciation and amortization and stock-based compensation, improved by 410 basis points to 32.9% of revenue, while total operating expenses improved by 210 basis points to 48.9% of revenue. We've put substantial money into our workforce during the last year to keep up with ongoing expansion across our businesses, and as a result, compensation and benefits rose 20.3% to $7.2 million. At the close of this quarter we had 222 employees, compared with 162 in the equivalent period a year ago. Stock compensation climbed 32% to $1.3 million, driven by granting more restricted stock units for new hires and to retain employees. Depreciation and amortization expense grew 39.9% to $2.2 million, largely because of amortizing ongoing improvements to our technology platform. For the quarter, we earned $2.2 million in net income, equal to $0.04 per fully diluted share. A year earlier, that figure stood at $1.4 million, or $0.03 per fully diluted share. A smaller income tax provision gave net income a boost, largely because of tax code changes made recently, though this gain was counterbalanced by a decline in net interest income, primarily related to the implied interest expense on future cash payments tied to the Gamma acquisition. Adjusted EBITDA for the third quarter, a non-GAAP metric that adds stock compensation back to EBITDA, reached $5 million, or $0.08 per diluted share, compared with $2.8 million, or $0.05 per diluted share, during the same period a year ago. When it came to the per-share figures, the diluted share counts we applied for those quarters came in at 61.8 million and 56.1 million, which works out to 5.7 million more shares. On the subject of how our company is doing financially, we closed the quarter with unrestricted cash on an adjusted basis totaling $16.9 million, and we carried no debt at all, thanks to robust cash flow from operations and the ongoing operational gains we're realizing from the Gamma acquisition. One thing to keep in mind: the adjustment made to our unrestricted cash balance accounts for the near-term effect of receivable and payable balances tied to our pharma patient affordability business. Let's now shift focus to our updated 2025 guidance, which includes Q3 actuals as of this point. We're lifting our revenue outlook to somewhere between $80.5 million and $81.5 million, which works out to 38.7% growth compared with last year when you look at the midpoint. We figure Plasma will account for roughly 57% of overall revenue, which is a slight increase from a year ago, and revenue from pharma patient affordability should come in at about 41% of the total, marking growth of more than 155% versus last year. For the full year, we're anticipating gross profit margins near 60%. Operating expenses should land somewhere in the $41.5 million to $42.5 million range, and that includes depreciation and amortization of about $8.4 million along with roughly $4.3 million in stock-based compensation. Looking ahead, we anticipate interest income around $2.6 million, a full-year tax rate of 18.7%, and roughly 59.76 million fully diluted shares. With all of those elements factored in, our net income guidance for the year has been lifted to a range of $7 million to $8 million, which works out to $0.12 to $0.13 per diluted share. For adjusted EBITDA, we now project somewhere between $19 million and $20 million, equal to $0.32 to $0.34 per diluted share. With that said, I'll turn things back over to the moderator so we can begin the Q&A session. Thank you.

Shyamali executive
#4

To take yourself out of the queue, you can press 2. The first person to ask something is Jacob Stephan, who is with Lake Street Capital Markets. Go ahead with what you'd like to ask.

Jacob Stephan analyst
#5

Hi, everyone. Thanks for letting us ask some things. Nice work on this quarter. First off, I was hoping you might walk us through a few of the points Mark raised regarding retail compared with specialty pharmacy. Is there a mix figure you can share at this point? Or perhaps you could also describe the pipeline mix between those two?

Matt Turner executive
#6

Hello. Matt Turner here. That data isn't something I have with me. Jeff is able to get back to you afterward on it; and we'd likely prefer to provide something closer to a percentage. Even so, at present we have a reasonable mix between retail and specialty. When you consider the pipeline heading into next year, more retail programs are being added — I'm not sure of the precise count. If you looked at total program count, the share going into next year is larger within the pipe, and that would involve essentially every stage of the pipeline that has a retail and a specialty piece.

Jacob Stephan analyst
#7

All right, I get it. It really does look like there could be a bit more upside here. Maybe, like you said, retail brings in higher claim volumes? Can you say a little more about that?

Matt Turner executive
#8

Sure. On the retail side, given the price of those products and how often they get prescribed — they treat much more of what I'd call everyday conditions — you tend to see a bigger portion of people receiving those drugs. Sometimes that's for a short-term issue. Sometimes it's a long-term one. If you were to look at the retail programs we have right now, we've got a few, you know, in spaces such as, let's say, pulmonary — so some inhalers, things like that. There are patients who get an inhaler because of asthma, and they'll need one every day for the rest of their lives. Then there are patients who come down with bronchitis, take it for a month or two, and then they're done. So the mix of utilization you see is usually a bit higher, which means a bigger number of patients in those programs. On the other hand, with a specialty drug, often, you know, the number of patients taking that medicine is obviously lower, because it's a specialty product. And usually you don't see a short-term indication for a specialty drug that we'd represent or that would have a program with us. So basically the ability to add more patients into the programs is usually higher with retail products than it is with specialty. That's why you'll see the higher claim volumes, and the offer value for a retail product is also going to be quite different. So patients won't necessarily hit their out-of-pocket max on a retail product the way they would on a specialty product. A specialty product is $25,000, and a patient has, you know, a $7,000 out-of-pocket max — they can hit their full out-of-pocket maximum, you know, in a couple of fills. But with a retail product where the offer value is, say, $200 or $300, they could use that 12 times a year. So instead of getting only two or three claims for that patient in the specialty space, we'd get 12 in the retail space.

Jacob Stephan analyst
#9

All right, I understand. That's really useful. Let's move to the second item. Jeff, you mentioned a bit about gross profit margins growing as the patient success center keeps ramping up. Could you help us think through how much capacity is being used right now, and perhaps where you anticipate things standing with these roughly 22 new centers, coming online during the back half or in the final quarter here?

Jeffery B. Baker executive
#10

Actually, I believe you're conflating two things. Regarding the centers, we never stated there would be 22; what we said was that during the latter six months of the year on the patient affordability pharma side, we would add somewhere between 20 and 30. As for the centers, honestly, heading toward the close of the year, we don't anticipate much movement there, perhaps a couple more or fewer. But that remark about most of them concerns those centers reaching the average of our core base. So certain fees generally don't begin until roughly 90 days later, when we start seeing the payoff from fully mature centers. Those centers have been operating for a good while, yet from a revenue opportunity standpoint, it simply requires time to materialize; for instance, inactivity fees and similar items; so as they mature further, and as we also observe a return to growth, and so on, I anticipate gross profit margins in the plasma business will improve compared with where they stood this quarter.

Jacob Stephan analyst
#11

All right, understood. Perhaps just one final item. I believe when you calculate the figures for Q4, and what you're telling us regarding pharma revenue growth, it suggests a quarter-over-quarter decline in average quarterly revenue for each program. Could you perhaps assist us in understanding what accounts for that discrepancy? And possibly compare it to what occurred this year versus last year, when there was actually a sequential increase from Q3 to Q4.

Jeffery B. Baker executive
#12

Yes. In the prior year, we had a greater number of newer programs with fewer claims. This year, we now have considerably more programs with claims, and those claims will decline during the second half of the year. It's a seasonal business, as Matt mentioned earlier, when everything resets. So that's what makes it different. We simply have more — it's a mixed issue, where the mix leans more toward claims rather than initial launch fees. Okay. I understand. I appreciate all the detail. Good job.

Jacob Stephan analyst
#13

Thanks. And the other point I want to make, Jacob, is that you shouldn't examine these figures in sequential order — though I do appreciate you raising the issue. The proper way to view them is year over year. In last year's fourth quarter, revenue per program came to $56,700. Compared with the prior year, that figure will rise; it will be higher year over year. This year, in the third quarter, we posted 75,434. A year ago, we recorded just shy of 50,000. So this business has to be assessed on a year over year basis. Looking at it sequentially means absolutely nothing. Okay. That's very helpful. Thank you.

Gary Prestopino analyst
#14

Yep. Thank you. Our next question comes from the line of Gary Prestopino with Barrington Research. Please proceed with your question. Hi, everyone. Is there — well, first of all, could you sort of explain what a mature program would generate in terms of average revenue, versus, you know, you mention 75,000 right now, but clearly you've got certain programs that are only now entering the mix or have just arrived — what does a mature program bring in? Each quarter?

Jeffery B. Baker executive
#15

Gary, it truly truly depends. I don't — I don't want to dodge or ignore the question, but the fact is we have programs generating $2,000 a month, and we have programs generating, you know, 20 times that amount. It simply comes down to the individual program. So once it's mature, I mean, we watch it feed into the numbers, and there are situations where a drug might do something and pick up another indication, which pushes that claim higher. On a year over year basis. For certain of these programs, once maturity hits, it's just, you know, more or less flat year over year. It's genuinely difficult to say. But defining what a mature program is — that's just too variable.

Gary Prestopino analyst
#16

Okay, let me ask this instead. When it comes to average revenues, does a specialty program differ from a standard retail program?

Matt Turner executive
#17

Yes. Gary, Matt here. Looking at the various product suites those programs rely on, we'd generally assign a higher value to a specialty program, assuming it carries the proper indications. That said, everything comes down to the mix, correct? I could rattle off 20 medications at this moment that you have never heard of. Right? Those drugs are completely unfamiliar to you; then I could list five that you do know. And you would think, oh, if you carry that medication, since I have watched 500 TV commercials about it, you must be generating enormous profits from it. That might be true, or it might not; it hinges on that drug's patient population. What is their age? Are most of them covered by Medicare? Do Medicaid patients make up the majority? Yes. It is an extremely complicated matter to examine this and conclude, okay, well, I recognize the name of some giant drug, and you picture golf, the golfers discussing their psoriatic arthritis. And you think, oh, well, that is a fantastic drug. Yeah; that might be the case because it is not affecting — the bulk of patients on that medication are not 70 years old and covered by Medicare; so that one could be good. But then I could mention other medications you know of that treat cancer; and, or Alzheimer's. And despite those being massive drugs for their company, for the manufacturer, they will not earn us anything. So you truly must examine how large a program will be depending on what the patient population is, correct? What is the segment of that patient population able to use our products; and then what other additional components can we layer on top? Mark brought up dynamic business rules. That exists within the specialty space. Right now we do not have that running on any of our retail programs. Therefore a specialty program that uses dynamic business rules will be much more profitable for us and generate higher top line revenue figures than a retail program that might handle 10 times the claim book. So it is — you genuinely must grasp the drugs specifically, their patient populations, and the cohorts among those patients who would possibly use copay within the overall eco or the overall patient counts.

Gary Prestopino analyst
#18

All right. That's useful on that point. There's really no way for you to know, to tie a drug to it, or for us to figure out what's going to add a layer. You just look — whether it's one drug, one program, or retail against specialty, as Jeff mentioned — at average revenue per program, quarter over quarter. Correct? Yeah. And I think, look, if we could — if our client allowed us to simply announce to you, we landed this brand — I think you folks would be much better off. Right? Because you'd say, oh, hey, I saw it on TV. When it comes to the people receiving that medication, the majority are going to be younger than 65. So there you go. Payson is likely to do quite well with it. Alternatively, since this is an oncology offering and it leans toward breast cancer, we'll probably see strong results from that program too. You could also look at what the manufacturer has shared about the size of that drug and the revenue it brings in. Sadly, that's not something we're able to do. Under almost all of our master services agreements, we're prohibited from revealing our clients' identities. Also, the labels we work with — it definitely isn't because we haven't tried hard enough to convince them to let us name those labels. If you go back to earlier calls when we could mention specific brands or specific customers, and if you, say, throw some questions into ChatGPT, you could probably piece together a clearer picture of what kinds of programs we currently have going. All right, and then Mark, you brought up this BECCS. You didn't know about this at all, so maybe you could explain it and how it will benefit you moving forward?

Mark R. Newcomer executive
#19

Yes. We call this a blood establishment computer system, or a BECCS. It's essentially a donor management system, and it lets us get into the plasma blood space; we've developed a suite of products. It's Software as a Service. That means, you know, we're working with a donor app, a plasma-specific CRM, and the donor management system. This gives us a distinct advantage — essentially, a whole new revenue stream that, once we get the FDA's green light, will let us begin moving forward along that route.

Gary Prestopino analyst
#20

Okay. Thanks. And thank you.

Peter Heckmann analyst
#21

The next person in the queue is Peter Heckmann from D. A. Davidson. Your line is open. Hi there, good afternoon, and I appreciate you taking my question. I'm wondering about the plasma segment — it's likely tough to break apart, but have you noticed any rise in donors because of problems tied to SNAP benefits being withheld? That was part of the government shutdown, and on the other side, what sort of pressure are you experiencing from greater ICE activity — detaining immigrants and deporting immigrants — when it comes to donors? On balance, do you believe those two things cancel each other out? Or might you just speak to whatever dynamics you're observing?

Jeffery B. Baker executive
#22

Peter, on that second point, I can say we have not observed any shift. Keep in mind that when someone donates plasma, an ID must be shown. That allows them to be tracked and so forth. Consequently, individuals present in The States illegally, lacking the right identification, are not permitted to give plasma. So there has been no impact at all tied to the change in our immigration population. Regarding the other matter with the shutdown, the shutdown has lasted only, you know, a couple of weeks. I have not seen — perhaps Mark has — but we truly have not seen any shift in the donors on that. Mark, what about you? Have you noticed anything? No; we haven't seen it.

Peter Heckmann analyst
#23

All right, I haven't laid eyes on it so far. Fine.

Mark R. Newcomer executive
#24

Nope. And honestly, at this stage I'm not truly anticipating that. Clearly, looking back, it appears things are beginning to ease somewhat as we head into Q4, and my guess is that easing will come during the back half of the year. That relates to the donor — specifically what we're engaged in with donors when it comes to payments. So what we're observing is that the payments going out are beginning to rise. And I'd anticipate that trend to keep going for roughly the coming six to twelve months.

Peter Heckmann analyst
#25

All right, got it. And regarding that second thing you mentioned — the CRM platform for donor management engagement — do you have any sense of when approval could arrive? And when it comes to gauging the size of that chance, would it be a situation with hundreds of customers, where every system might run into the hundreds of thousands of dollars? Or what frame should we use to evaluate the possible upside?

Mark R. Newcomer executive
#26

Yeah. What I'd say is, we had been set to secure FDA approval at some point during Q4. Moving into Q1. Naturally, we hadn't anticipated the shutdown, and we definitely didn't think it would stretch on for this long. Clearly, that's going to set us back, likely to Q1, Q2. With luck, sooner. As for how to frame it — no. In the US market, there's a figure you can easily find for the total number of clients operating there. I wouldn't say hundreds. Of clients across the US market. That said, there's a great deal on a location-by-location basis that we'd be licensing, yet it's still early, and I'd rather not dive into the specifics of the model we'll use to approach this right now.

Peter Heckmann analyst
#27

Okay, then. Just keep watching. Thanks for that.

Mark R. Newcomer executive
#28

Answerer Mark R. Newcomer: Yeah. You're welcome. Thanks.

Shyamali analyst
#29

Just a quick note that if anyone has further questions — and with that, our Q&A portion has wrapped up. I'll hand things back over to Mark Newcomer for his closing comments.

Mark R. Newcomer executive
#30

Thanks. Clearly, we take pride in what we've accomplished. We feel good about what lies ahead. We're committed to driving meaningful growth and creating lasting value for shareholders. And we can't wait to share our next update with all of you in the coming quarter.

Shyamali analyst
#31

Appreciate it. That wraps up the call for today. You're free to hang up your phones now. Thanks for joining us.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Paysign, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Paysign, Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.